Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • ID: 4451353
  • Report
  • 71 pages
  • P&S Market Research
1 of 3
PSP therapeutics pipeline in 2017

The study analyzed that PSP therapeutics pipeline comprises approximately 14 drug candidates in different stages of development. The exact cause of PSP is unknown, but it has been observed that PSP is the accumulation of abnormal deposits of the tau protein in nerve cells in the brain, and eventual toxicity in nerve cells in the brain stem. The appearance of deposits of the microtubule-associated tau protein termed ‘neurofibrillary tangles’ is a common feature of tauopathies and development of progressive supranuclear palsy.

Insights on pipeline segments

According to the research findings, most of the drug candidates in PSP therapeutics pipeline are being developed as small molecule agents. Also, majority of the pipeline drug candidates are being developed using the oral route of administration.

Maximum drugs being developed as small molecule

Many companies are more focused on developing their drug candidate’s as small molecule, since small molecule can easily pass through the blood brain barrier due to their low molecular weight and small size.

Various collaborations taking place for PSP drug development

In April 2017, Biogen Inc. entered into an exclusive worldwide license agreement with Bristol-Myers Squibb Company to develop and commercialize BMS-986168, a Phase II investigational medicine for the treatment of Alzheimer’s disease (AD) and PSP. Some of the key players developing drugs for the treatment of progressive supranuclear palsy include AbbVie Inc., Biogen Inc., Asceneuron SA, Alzprotect SAS and others.

PSP Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Progressive Supranuclear Palsy Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Progressive Supranuclear Palsy Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase II/III: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.4 Pre-Clinical: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Progressive Supranuclear Palsy Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Progressive Supranuclear Palsy Therapeutics Pipeline

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Progressive Supranuclear Palsy Therapeutics Pipeline
7.2 SWOT Analysis of Progressive Supranuclear Palsy Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Progressive Supranuclear Palsy Therapeutics, By Company (2017)
Description Of Phase II/III Drug Candidates
Clinical Trials Of Phase II/III Drug Candidates
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Inactive Psp Drug Candidates
Discontinued Psp Drug Candidates
Companies - at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Progressive Supranuclear Palsy Therapeutics Drug Candidates Under Development (2017)
Progressive Supranuclear Palsy Therapeutics Pipeline Split, By Molecule Type (2017)
Progressive Supranuclear Palsy Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll